You are here

Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)

Last updated on April 23, 2019

FOR MORE INFORMATION
Study Location
IDIAP Jordi Gol
Barcelona, Cataluña, 8007 Spain
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Atrial Fibrillation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Patients more than 18 years-old.

2. Patients diagnosed with NVAF registered in primary care according to ICD-10.

3. Patients initiating apixaban (naïve or VKA experienced), VKA (naïve or VKA
experienced), dabigatran or rivaroxaban for the SPAF indication.

4. Continuous enrolment in the 12 months pre-index.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Patients with valvular heart disease (ICD 10: I05.0-I05.09, I08.0-I08.9) including
patients with mitral prosthetic valves.

2. Lost to follow-up (e.g. transfer to primary care center non-ICS).

NCT03441633
Pfizer
Completed
Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Atrial Fibrillation
NCT03572972
All Genders
0+
Years
Seoul,

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now